ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
Dow Jones
39.127,80
0,04%
Euro vs US Dollar
1,06909
0,10%
Bitcoin
61.043,53
0,38%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. First Wave BioPharma Inc (FWBI)

  7. First Wave BioPharma Inc (FWBI) News

FWBI

First Wave BioPharma (FWBI)

First Wave BioPharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:FWBI
DatumZeitQuelleÜberschriftSymbolFirma
24/06/202414h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FWBIFirst Wave BioPharma Inc
20/06/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FWBIFirst Wave BioPharma Inc
17/06/202423h23Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:FWBIFirst Wave BioPharma Inc
14/06/202423h15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:FWBIFirst Wave BioPharma Inc
11/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FWBIFirst Wave BioPharma Inc
05/06/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FWBIFirst Wave BioPharma Inc
31/05/202423h25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:FWBIFirst Wave BioPharma Inc
30/05/202423h32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:FWBIFirst Wave BioPharma Inc
30/05/202423h18Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:FWBIFirst Wave BioPharma Inc
16/05/202413h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FWBIFirst Wave BioPharma Inc
16/05/202413h00GlobeNewswire Inc.First Wave BioPharma Changes Name to Entero TherapeuticsNASDAQ:FWBIFirst Wave BioPharma Inc
14/05/202423h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FWBIFirst Wave BioPharma Inc
13/05/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FWBIFirst Wave BioPharma Inc
13/05/202422h59Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FWBIFirst Wave BioPharma Inc
10/05/202413h55GlobeNewswire Inc.First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketNASDAQ:FWBIFirst Wave BioPharma Inc
09/05/202413h00GlobeNewswire Inc.First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthNASDAQ:FWBIFirst Wave BioPharma Inc
08/05/202423h16Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:FWBIFirst Wave BioPharma Inc
24/04/202413h00GlobeNewswire Inc.First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsNASDAQ:FWBIFirst Wave BioPharma Inc
17/04/202413h00GlobeNewswire Inc.First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseNASDAQ:FWBIFirst Wave BioPharma Inc
15/04/202413h00GlobeNewswire Inc.First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
18/03/202412h00GlobeNewswire Inc.First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
14/03/202411h00GlobeNewswire Inc.First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineNASDAQ:FWBIFirst Wave BioPharma Inc
05/03/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FWBIFirst Wave BioPharma Inc
05/03/202413h00GlobeNewswire Inc.First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
04/03/202423h29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FWBIFirst Wave BioPharma Inc
04/03/202414h00GlobeNewswire Inc.First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct OfferingNASDAQ:FWBIFirst Wave BioPharma Inc
13/02/202413h00GlobeNewswire Inc.First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024NASDAQ:FWBIFirst Wave BioPharma Inc
23/01/202413h00GlobeNewswire Inc.First Wave BioPharma to Present at the DealFlow MicroCap ConferenceNASDAQ:FWBIFirst Wave BioPharma Inc
18/01/202422h01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:FWBIFirst Wave BioPharma Inc
18/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FWBIFirst Wave BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:FWBI

Kürzlich von Ihnen besucht

LSE
78NG
Ras Khaimah40
DGFX
QAUSDT
Quantum Assets Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten